Related Experiment Video
Updated: Aug 20, 2026

A Versatile Murine Model of Subcortical White Matter Stroke for the Study of Axonal Degeneration and White Matter Neurobiology
Published on: March 17, 2016
Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia
E-Jian Lee1, Ming-Yang Lee, Hung-Yi Chen
1Neurophysiology Laboratory, Neurosurgical Service, Department of Surgery and Institute of Biomedical Engineering, National Cheng Kung University Medical Center and Medical School, Tainan, Taiwan. eijan@mail.ncku.edu.tw
Abstract:
We have previously shown that melatonin reduces infarct volumes and enhances neurobehavioral and electrophysiological recoveries following transient middle cerebral artery (MCA) occlusion in rats. In the study, we examined whether melatonin would display neuroprotection against neuronal, axonal and oligodendrocyte pathology after 24 hr of reperfusion following 1 hr of MCA occlusion in mice. Melatonin (5 mg/kg) or vehicle was given intraperitoneally at the commencement of reperfusion. Neurological deficits were assessed 24 hr after ischemia. Gray matter damage was evaluated by quantitative histopathology. Axonal damage was determined with amyloid precursor protein and microtubule-associated protein tau-1 immunohistochemistry to identify postischemic disrupted axonal flow and oligodendrocyte pathology, respectively. Oxidative damage was assessed by 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 4-hydroxynonenal (4-HNE) immunohistochemistry. Relative to controls, melatonin-treated animals not only had a significantly reduced volume of gray matter infarction by 42% (P<0.001), but also exhibited a decreased score of axonal damage by 42% (P<0.001) and a reduction in the volume of oligodendrocyte pathology by 58% (P<0.005). Melatonin-treated animals also had significantly reduced immunopositive reactions for 8-OHdG and 4-HNE by 53% (P<0.001) and 49% (P<0.001), respectively. In addition, melatonin improved sensory and motor neurobehavioral outcomes by 47 and 30%, respectively (P<0.01). Thus, delayed (1 hr) treatment with melatonin reduced both gray and white matter damage and improved neurobehavioral outcomes following transient focal cerebral ischemia in mice. The finding of reduced oxidative damage observed with melatonin suggests that its major mechanisms of action are mediated through its antioxidant and radical scavenging activity.
Insights
Melatonin treatment significantly reduced brain damage and improved neurological function in mice after stroke. This neuroprotection is linked to melatonin's antioxidant properties, suggesting a therapeutic role in stroke recovery.
Area of Science:
- Neuroscience
- Pharmacology
- Stroke Research
Background:
- Transient middle cerebral artery (MCA) occlusion is a common model for studying ischemic stroke.
- Melatonin has demonstrated neuroprotective effects in previous studies involving stroke models.
Purpose of the Study:
- To investigate the neuroprotective effects of melatonin against neuronal, axonal, and oligodendrocyte pathology in a mouse model of focal cerebral ischemia.
- To evaluate the impact of melatonin on neurobehavioral outcomes and oxidative damage following ischemic stroke.
Main Methods:
- Mice underwent 1 hour of MCA occlusion followed by 24 hours of reperfusion.
- Melatonin (5 mg/kg) or vehicle was administered intraperitoneally at the start of reperfusion.
- Neurological deficits, gray matter infarction, axonal damage, oligodendrocyte pathology, and oxidative stress markers (8-OHdG, 4-HNE) were assessed.
Main Results:
- Melatonin treatment significantly reduced gray matter infarction by 42% (P<0.001).
- Melatonin decreased axonal damage by 42% (P<0.001) and oligodendrocyte pathology by 58% (P<0.005).
- Significant reductions in oxidative damage markers (8-OHdG by 53%, 4-HNE by 49%) and improvements in neurobehavioral outcomes (sensory by 47%, motor by 30%) were observed.
Conclusions:
- Delayed treatment with melatonin effectively reduced both gray and white matter damage following transient focal cerebral ischemia in mice.
- Melatonin's antioxidant and radical scavenging activities are likely key mechanisms underlying its neuroprotective effects in stroke.
- Melatonin shows promise as a therapeutic agent for improving outcomes after ischemic stroke.

